---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038094"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:00:45.100826+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027

## Summary
- Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.
- Patient 1 maintained ~50% HBsAg reduction 7 months after initial dose, indicating durable antiviral editing.
- Cohort 2 (0.4 mg/kg) shows no Grade 3+ AEs; DMC approved escalation to Cohort 3.
- Cash runway extended to H2 2027 via ~$25M annual operating expense reduction program starting July 2025.
- Dr. Mark Sulkowski appointed Head Clinical Development Advisor for PBGENE-HBV and later-stage trials.

## SEC filing metadata
- accession: 0001628280-25-038094
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828025038094/0001628280-25-038094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828025038094/dtil-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038094
- JSON: https://secwatch.observer/filing/0001628280-25-038094.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.